Literature DB >> 17698862

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Stephen B Hanauer1.   

Abstract

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17698862      PMCID： PMC1954967          DOI： 10.1136/gut.2006.115980

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  41 in total

Review 1.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Authors:  William J Sandborn; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

Review 2.  Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.

Authors:  Karin Ekström Smedby; Eva Baecklund; Johan Askling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

3.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

4.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

5.  Infliximab in Crohn's disease: first anniversary clinical experience.

Authors:  R D Cohen; J F Tsang; S B Hanauer
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

6.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

7.  Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Authors:  Gerald A Dayharsh; Edward V Loftus; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Thomas E Witzig; William R Macon; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

8.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 9.  Immunosuppressive drugs and cancer.

Authors:  Thierry Vial; Jacques Descotes
Journal:  Toxicology       Date:  2003-04-01       Impact factor: 4.221

10.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321
View more
  12 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

2.  Biologic therapy for inflammatory bowel disease comes of age.

Authors:  Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2008-12

3.  The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.

Authors:  Gert Van Assche
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-03

Review 4.  State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.

Authors:  Dario Sorrentino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-07       Impact factor: 46.802

Review 5.  Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?

Authors:  S M Everett; P J Hamlin
Journal:  Frontline Gastroenterol       Date:  2011-04-04

6.  Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis.

Authors:  Hideaki Hozumi; Ryota Hokari; Chie Kurihara; Kazuyuki Narimatsu; Hirokazu Sato; Shingo Sato; Toshihide Ueda; Masaaki Higashiyama; Yoshikiyo Okada; Chikako Watanabe; Shunsuke Komoto; Kengo Tomita; Atsushi Kawaguchi; Shigeaki Nagao; Soichiro Miura
Journal:  Int J Colorectal Dis       Date:  2013-02-03       Impact factor: 2.571

Review 7.  Diagnosis and management of fistulizing Crohn's disease.

Authors:  Ole Haagen Nielsen; Gerhard Rogler; Dieter Hahnloser; Ole Østergaard Thomsen
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-01-20

8.  Biologic therapy for inflammatory bowel disease comes of age.

Authors:  Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

Review 9.  Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Mehmet Coskun; Casper Steenholdt; Nanne K de Boer; Ole Haagen Nielsen
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 5.577

Review 10.  Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.

Authors:  Bruno Rafael Ramos de Mattos; Maellin Pereira Gracindo Garcia; Julia Bier Nogueira; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luís Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.